Joyzyme Group EBIT per Employee
The EBIT per Employee of Joyzyme Group (8622.HK) as of Jul 26, 2026 is -123,639.56 CNY. In the previous year, EBIT per Employee was -68,643.84 CNY — a change of 80.12% (lower).
Get this data via API
Financial Data API
EBIT per Employee
-123,639.56CNY
YoY
80.12%
Last updated:
EBIT per Employee of Joyzyme Group is 2026 -123,639.56 CNY. EBIT per Employee of Joyzyme Group was 2025 -68,643.84 CNY. It decreases by 80.12% lower compared to the previous year.
Access this data via the Eulerpool API
Joyzyme Group Stock analysis
What does Joyzyme Group do? Huakang Biomedical Holdings Co Ltd is a leading company in the field of biomedical research and development. It was founded in 2004 and is headquartered in Shenzhen, China. The company is listed on the Hong Kong Stock Exchange (HKEX: 8622) and has branches in various countries, including Germany and the USA.
Answer: Huakang Biomedical Holdings Co Ltd is a leading company in the field of biomedical research and development. It was founded in 2004 and is headquartered in Shenzhen, China. The company is listed on the Hong Kong Stock Exchange (HKEX: 8622) and has branches in various countries, including Germany and the USA. Joyzyme Group is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Joyzyme Group stock
EBIT per Employee of Joyzyme Group is -123,639.56 CNY in 2026.
Access this data via the Eulerpool API
Workforce — Joyzyme Group
All Key Metrics — Joyzyme Group
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth